Sun Pharma agrees to supply at MFN pricing to U.S. medicaid programmes
The U.S. is the company’s largest market for innovative medicines and a cornerstone of its long-term growth strategy, generating approximately 27% of the company’s global revenue.
5News aggregated this summary from the outlet’s public feed. The full article, with all the context, is on www.thehindu.com — the content belongs to The Hindu - Sci-Tech.
